Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Zdravljenje metastatskega diferenciranega raka ščitnice z radiojodom ob rhTSH
Authors:ID Žagar, Ivana (Author)
Files:.pdf PDF - Presentation file, download (205,46 KB)
MD5: 615C2C64A93E72EC3CE1F7916E16E365
PID: 20.500.12556/dirros/36bbfa91-54a5-4b2f-9e5e-4ef247dd6e0c
 
Language:Slovenian
Typology:1.04 - Professional Article
Organization:Logo OI - Institute of Oncology
Publication status:Published
Publication version:Version of Record
Year of publishing:2009
Number of pages:str. 26-30
Numbering:Letn. 13, št. 1
PID:20.500.12556/DiRROS-9051 New window
UDC:616-006
ISSN on article:1408-1741
URN:URN:NBN:SI:doc-VQ77C4JS
COBISS.SI-ID:25712857 New window
Copyright:by Authors
Note:BSDOCID145249;
Publication date in DiRROS:31.08.2018
Views:2692
Downloads:644
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija. strokovni časopis za zdravnike
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:31.08.2018

Secondary language

Language:English
Abstract:A serum thyroid-stimulating hormone (TSH) level of > 30 mU/L, which is necessary for reliable testing and efficient radioiodine therapy in patients with differentiated thyroid carcinoma, may be achieved by a 4-6 week-L-thyroxin withdrawal or by application of recombinant human TSH (rh TSH). The purpose of our study was to test the efficacy of 131-I therapy (RIT) using recombinant human TSH (rhTSH) as an alternative in the patients with differentiated thyroid carcinoma (DTC) in whom endogenous TSH stimulation was not an option due to the poor patient’s physical condition during the hypothyroid state or due to the disease progression during L-thyroxin withdrawal. The study comprised 18 patients (13 females, 5 males, aged 37-79, median 73 years), with histologically proven DTC, in whom the primary diagnosis was established between 1993-2000. These patients underwent total or near-total thyroidectomy and received radioiodine ablation and 1-12 (median 5) RITs after L-thyroxin withdrawal, with a cumulative dose ranging 1.1 – 50.73 GBq (median 24.70 GBq). While on L-thyroxin after rhTSH administration (rhTSH RIT) they received altogether 46 RITs: four patients received one, 6 had 2, 3 had 3, 4 had four and 1 had 5 rhTSH–aided RITs. rhTSH (0.9 mg, i.m.), administered in two consecutive days, was followed by 131-I therapeutic dose (5.2-7.6 GBq) on the third day; 2-5 days later, post-therapeutic whole-body scan (PTWBS) was performed. The efficacy of rhTSH RIT was evaluated by thyroglobulin (Tg) measurement and/or follow-up radioiodine whole body scans (WBS) 2 to 12 months after rhTSH RIT. Results: Altogether 60 131-I-avid lesions were detected on PTWBS. Six to 12 months after the first rhTSH-aided RIT, partial response was achieved in 4/18 (22%). Stable disease was achieved in 3/18 patients (17%). In most patients (n=11, 61%), disease progressed despite rh TSH-aided RITs: a continuous progression was seen and Tg increased up to max 3500%, the Tg level changes being consistent with the results of post-RIT WBSs and the other follow-up modalities. The rhTSH was well-tolerated by most of the patients and side effects in all but one were mild. Conclusion: rhTSH-aided RIT proved to add some therapeutic benefit in at least 39% of our patients with metastatic DTC, who otherwise could not be efficiently treated with 131-I. The diversity of the other therapeutic approaches (previous RITs under endogenous TSH stimulation, external-beam radiotherapy, chemotherapy) applied within a relatively short time before rhTSH-aided RIT even in well-responding patients did not allow us to attribute the tumor and metabolic response just and only to RIT under rhTSH stimulation.


Archive

niGradiv

Back